Intellia Therapeutics’ $300 Million Common Stock Offering

Goodwin Procter represented Intellia Therapeutics, while Latham & Watkins LLP represented the underwriter in the offering.Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on…

This content is for members only.
Login to Read More Join Now
Laura Testa

Author: Laura Testa

This content is for members only.
Login to Read More Join Now